Post by Tony Crispino on Oct 27, 2017 8:10:41 GMT -8
The Fall 2017 event for SWOG brought about the finalization of the phase III cyto-reductive trial for metastatic men. The trial will hit the streets in Q1 2018 and is called trial S1802. I'll be on that panel for ten years. But that's not the new panels I am joining.
As of yesterday I was elected to the National Cancer Institute (NCI) GU Cancers Prostate Cancer Task Force. This is a 3 year term. Very nice to even be considered I am certainly excited to be appointed.
The American Society of Clinical Oncology has also appointed me to their molecular guidelines panel. This will be an interesting panel to serve on as we truly need to define the research moving forward. We lack so much Level 1 data here but it's here that targeted and individualized therapies will be derived from.
Lastly, The Movember Foundations has appointed me to help them define their research targets for the next few years. This mens health foundation has been instrumental in brining the spotlight to the world community on mens cancers.
I look forward to a fun year being able to branch out into the community in the name of cancer research. Never imagined being highly regarded and respected by the researchers and foundations. But i will do my very best for those that are investing time with me.